MedTrace Logo

AVODART(Dutasteride) Post-marketing Surveillance(PMS)

NCT01299571 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3977

Last updated 2017-07-05

Study results available
· View outcomes & findings →

Summary

An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of AVODART administered in Korean BPH patients according to the prescribing information

Conditions

  • Benign Prostatic Hyperplasia
  • Prostatic Hyperplasia

Interventions

DRUG

Dutasteride

Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01299571 on ClinicalTrials.gov